Gainey McKenna & Egleston Announces Class Action Lawsuit Against…
A class action lawsuit has been filed against BioAge Labs Inc. (BIOA), according to a recent announcement from legal firm Gainey McKenna & Egleston. The lawsuit is based on allegations that BioAge Labs Inc. made materially false and/or misleading statements and failed to disclose crucial information regarding its business operations and prospects.
Investors who purchased BioAge Labs Inc. securities between May 14, 2021, and July 16, 2021, are encouraged to participate in the lawsuit. The deadline to seek the role of lead plaintiff in the case is September 27, 2021.
The allegations against BioAge Labs Inc. include claims that the company made false and misleading statements about the efficacy of its lead product candidate, BGE-175, a drug intended for treatment of hematologic malignancies. It is also alleged that the company failed to disclose that its drug candidate was not as effective as it claimed, and that this could have a negative impact on BioAge Labs Inc.’s financial performance.
Investors who suffered losses are encouraged to contact Gainey McKenna & Egleston to discuss their legal rights. The litigation seeks to recover damages on behalf of investors who may have been misled by BioAge Labs Inc.’s alleged misrepresentations.
It is important for investors to stay informed about developments in the securities market and to seek legal counsel if they believe their rights have been violated. We will continue to monitor this case and provide updates as new information becomes available.
